Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Polycystic Kidney Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2016, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape. Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 11 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Polycystic Kidney Disease. Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Polycystic Kidney Disease Overview 8 Therapeutics Development 9 Pipeline Products for Polycystic Kidney Disease - Overview 9 Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 10 Polycystic Kidney Disease - Therapeutics under Development by Companies 11 Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 12 Polycystic Kidney Disease - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Polycystic Kidney Disease - Products under Development by Companies 16 Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 17 Polycystic Kidney Disease - Companies Involved in Therapeutics Development 18 Angion Biomedica Corp. 18 Aptevo Therapeutics Inc 19 DiscoveryBiomed, Inc. 20 Endocyte, Inc. 21 IC-MedTech, Inc. 22 Ipsen S.A. 23 Kadmon Corporation, LLC 24 ManRos Therapeutics 25 Metabolic Solutions Development Company, LLC 26 NovaTarg Therapeutics, Inc 27 Otsuka Holdings Co., Ltd. 28 XORTX Pharma Corp. 29 Polycystic Kidney Disease - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 (ascorbic acid + menadione) - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 ANG-3070 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 CIM-2 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 CR-8 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 DBM-43H11 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Drugs for Polycystic Kidney Disease - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 EC-0371 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 JP-153 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 lanreotide acetate - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 menadione sodium bisulfite - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 MSDC-0160 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 MSDC-0602 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 oxypurinol - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 pyrimethamine - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 STA-2842 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 tesevatinib tosylate - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 TNFR x TWEAKR - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 tolvaptan - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Polycystic Kidney Disease - Dormant Projects 73 Polycystic Kidney Disease - Discontinued Products 74 Polycystic Kidney Disease - Product Development Milestones 75 Featured News & Press Releases 75 Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease 75 Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 76 May 28, 2015: Otsuka's JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 76 Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented "dual action" small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases 77 Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 78 Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 79 Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 79 Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide 81 Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease 82 Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 82 May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease 83 Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease 83 Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease 84 Aug 29, 2013: Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease 84 Aug 05, 2013: U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease 85 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 86 Disclaimer 87
List of Tables
Number of Products under Development for Polycystic Kidney Disease, H2 2016 9 Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp., H2 2016 18 Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H2 2016 19 Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H2 2016 20 Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H2 2016 21 Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H2 2016 22 Polycystic Kidney Disease - Pipeline by Ipsen S.A., H2 2016 23 Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H2 2016 24 Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2016 25 Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2016 26 Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 27 Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 28 Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp., H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Assessment by Combination Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Polycystic Kidney Disease - Dormant Projects, H2 2016 73 Polycystic Kidney Disease - Discontinued Products, H2 2016 74
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.